On The Edge of Validation – Cancer Protease Fibroblast Activation Protein

Author(s): Beni B. Wolf, Clifford Quan, Thuy Tran, Christian Wiesmann, Daniel Sutherlin

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 8 , Issue 7 , 2008

Become EABM
Become Reviewer
Call for Editor


Numerous studies implicate the prolyl peptidase, fibroblast activation protein (FAP) in tumorigenesis; however, FAP-selective inhibitors have not yet been developed to fully validate FAP as a therapeutic target. Herein, we review recent efforts aimed at validating and inhibiting FAP for cancer therapy and highlight future directions for successful targeting of this prolyl peptidase.

Keywords: FAP, DPP4, dipeptidyl peptidase, prolyl peptidase, inhibitor, cancer

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Published on: 01 March, 2012
Page: [719 - 727]
Pages: 9
DOI: 10.2174/138955708784567449
Price: $65

Article Metrics

PDF: 21